{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-038802","form_type":"8-K","ticker":"SSKN","cik":"0001051514","company_name":"STRATA Skin Sciences, Inc.","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.025664+00:00","generated_at":"2026-06-11T21:12:03.328874+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"STRATA Skin Sciences Q2 revenue $8.3M, net loss $3.1M; FY guidance cut to $35-38M","bullets":["Q2 revenue $8.3M vs $9.1M YoY; equipment revenue down to $2.8M from $3.5M due to $1.5M one-time China sale last year.","Net loss $3.1M ($0.09 loss per share) vs $1.9M ($0.05 loss) YoY; adjusted EBITDA loss of $95K vs positive $207K.","FY 2023 guidance revised to $35-38M from prior; cites slowdown in capex and macro factors impacting equipment sales.","Secured up to $12M financing with MidCap Financial; cash balance $10.4M; includes refinancing and $7M new tranche.","73 TheraClear X devices placed; initiated acne clinical study; JCAD publication released."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-038802","json":"https://secwatch.observer/filing/0001140361-23-038802.json","markdown":"https://secwatch.observer/filing/0001140361-23-038802.md","text":"https://secwatch.observer/filing/0001140361-23-038802.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1051514/000114036123038802/0001140361-23-038802-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1051514/000114036123038802/brhc20057162_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T21:12:03.328874+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"99c0f9450bbf5b79a9602b5656472c0deb14f6ea","claim":"STRATA Skin Sciences, Inc. reported second quarter ended June 30, 2023 results: revenue $8.3 million, net income $3.1 million, or a loss of $0.09 per basic and diluted common share, EPS $0.09 loss per basic and diluted common share. Guidance lowered.","evidence_excerpt":"today announced financial results for the second quarter ended June 30, 2023. Second Quarter 2023 and Recent Business Highlights: ● Revenues in the second quarter of 2023 were $8.3 million, compared to $9.1 million for the second quarter of 2022. ● Secured up to an additional $12 million financing with MidCap Financial. ● Placed 73 TheraClear ® X devices as of June","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1051514/000114036123038802/0001140361-23-038802-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Revenue","value":"$8.3 million"},{"label":"Net income","value":"$3.1 million, or a loss of $0.09 per basic and diluted common share"},{"label":"EPS","value":"$0.09 loss per basic and diluted common share"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}